Related Experiment Video
Updated: Dec 26, 2025
Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
Published on: October 10, 2025
Bortezomib and bilateral herpes zoster
Nicola di Meo1, Serena Bergamo, Adina Dondas
1University of Trieste, Department of Dermatology and Venereology, Trieste, Italy. nickdimeo@libero.it
Bortezomib treatment for multiple myeloma may increase the risk of varicella zoster virus (VZV) reactivation. Antiviral prophylaxis with acyclovir is recommended for patients undergoing bortezomib therapy to prevent herpes zoster.
Area of Science:
- Oncology
- Infectious Diseases
- Pharmacology
Background:
- Bortezomib is a proteasome inhibitor widely used for multiple myeloma treatment.
- There is ongoing discussion regarding the risk of varicella zoster virus (VZV) reactivation in multiple myeloma patients during bortezomib therapy.
More Related Videos
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
07:02Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
Published on: September 14, 2010